“Edison’s accessible and high-quality research gives us the opportunity to communicate an independent perspective of Tyman to a wide variety of potential stakeholders.”
Antisense Therapeutics is an Australia-based biopharmaceutical company developing and commercialising Antisense pharmaceuticals for rare diseases. The company’s lead clinical asset is ATL1102, an ASO therapy being investigated for the treatment of DMD.
Managing Director - Head of Content, Healthcare
| % | 1M | 3M | 12M |
|---|---|---|---|
| Actual | (8.6) | (1.1) | (33.3) |
| Relative | (5.6) | (0.5) | (29.0) |
| 52 week high/low | A$0.1/A$0.1 |
Antisense Therapeutics is an Australian biotechnology company developing antisense oligonucleotide (ASO) therapies for the treatment of rare diseases. Its lead asset, ATL1102, is being investigated as a targeted anti-inflammatory therapy to treat Duchenne muscular dystrophy (DMD). In a positive strategic pivot, trial design was amended to a smaller Phase IIb study (n=42 vs 108) that should provide a nearer-term catalyst, if positive readouts are achieved. As a result of the reduced trial costs, the company’s cash runway is anticipated to be extended (net cash at end-June 2022 of A$19.2m) into Q4 CY23. Management envisages a need to raise funds in the mid-single digit (A$m) region, which it anticipates will fund operations to trial readouts in Q124.
Get access to the very latest content matched to your personal investment style.
